Literature DB >> 8658047

Co-stimulation and co-inhibition: equal partners in regulation.

N R Sinclair1, C C Anderson.   

Abstract

Specific immune responses are controlled by two counterbalancing mechanisms-co-stimulation and co-inhibition. Antigen receptors determine specificity, activate co-stimulation and/or co-inhibition, and interact with these co-stimulatory/co-inhibitory mechanisms to dictate the direction of the immune response, either positive or negative. Co-stimulatory or co-inhibitory ligands interact with their specific receptors and may indicate the context in which antigen is perceived by lymphocytes. Ligation of antigen receptors may activate only co-stimulatory or co-inhibitory mechanisms, and thus may influence secondarily the direction of the immune response. Furthermore, the activity of a given co-stimulator or co-inhibitory receptor is modified depending on signalling via the antigen receptor. If neither co-stimulators nor co-inhibitors are present, lymphocytes, activated in response to antigen receptor signalling, produce low levels of effector elements and then revert to inactivity. Co-inhibitors are defective in autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8658047     DOI: 10.1046/j.1365-3083.1996.d01-267.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  10 in total

1.  Co-inhibitory molecules: Controlling the effectors or controlling the controllers?

Authors:  Govindarajan Thangavelu; Christa Smolarchuk; Colin C Anderson
Journal:  Self Nonself       Date:  2010-02-16

2.  Visualization of negative signaling in B cells by quantitative confocal microscopy.

Authors:  H Phee; W Rodgers; K M Coggeshall
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

3.  The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants.

Authors:  Govindarajan Thangavelu; Kenneth M Murphy; Hideo Yagita; Louis Boon; Colin C Anderson
Journal:  Immunobiology       Date:  2011-01-12       Impact factor: 3.144

4.  Lipopolysaccharide-activated dendritic cells: "exhausted" or alert and waiting?

Authors:  Kaveh Abdi; Nevil J Singh; Polly Matzinger
Journal:  J Immunol       Date:  2012-05-04       Impact factor: 5.422

Review 5.  The history of the two-signal model of lymphocyte activation: A personal perspective.

Authors:  Peter A Bretscher
Journal:  Scand J Immunol       Date:  2019-03-18       Impact factor: 3.487

Review 6.  Defending and integrating an organism by the immune system.

Authors:  Zlatko Dembic
Journal:  Scand J Immunol       Date:  2022-05       Impact factor: 3.889

7.  Are major histocompatibility complex molecules involved in the survival of naive CD4+ T cells?

Authors:  Isabelle Grandjean; Livine Duban; Elizabeth A Bonney; Erwan Corcuff; James P Di Santo; Polly Matzinger; Olivier Lantz
Journal:  J Exp Med       Date:  2003-09-29       Impact factor: 14.307

8.  PD-1 Controls Tonic Signaling and Lymphopenia-Induced Proliferation of T Lymphocytes.

Authors:  Kristofor K Ellestad; Jiaxin Lin; Louis Boon; Colin C Anderson
Journal:  Front Immunol       Date:  2017-10-12       Impact factor: 7.561

9.  Proliferative vitreoretinopathy may be a risk factor in combined macular hole retinal detachment cases.

Authors:  Matthew A Cunningham; Ryan M Tarantola; James C Folk; Elliott H Sohn; H Culver Boldt; Jordan A Graff; Korianne Elkins; Stephen R Russell; Vinit B Mahajan
Journal:  Retina       Date:  2013-03       Impact factor: 4.256

Review 10.  Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis.

Authors:  Boris Shulgin; Yuri Kosinsky; Andrey Omelchenko; Lulu Chu; Ganesh Mugundu; Sergey Aksenov; Rodrigo Pimentel; Garrett DeYulia; Geoffrey Kim; Kirill Peskov; Gabriel Helmlinger
Journal:  Oncoimmunology       Date:  2020-05-21       Impact factor: 8.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.